"paper"

For August 2020, we have selected Turner R.S. et al. “Nilotinib Effects on Safety, Tolerability,and Biomarkers in Alzheimer’s Disease” Annals of Neurology 2020;88:183–194. doi: 10.1002/ana.25775. Epub 2020 May 28.

For August 2020, we have selected Rogers J.P. et al. “Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic” Lancet Psychiatry 2020; 7:611-627.

For July 2020, we have selected: Yang P. et al. Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke

For June 2020, we have selected: Mao L. et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China JAMA

For 2020, we have selected: Shahnawaz M, Mukherjee A, Pritzkow S et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy.

For May 2020, we have selected: Lechien JR, Chiesa-Estomba CM, De Siati DR et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild‑to‑moderate forms of the coronavirus disease (COVID‑19): a multicenter European study.

In these troubled times, our Paper of the Month for April is: Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the Covid-19 outbreak in Lombardy, Italy: Early experience and forecast during an emergency response.

For March 2020, we have selected: Olanow et al, Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurology; 19: 135-44.

For February 2020, we have selected: Kleine-Borgmann J, Schmidt K, Hellmann A, Bingel U. Effects of open-label placebo on pain, functional disability, and spine mobility in patients with chronic back pain: a randomized controlled trial.

For January 2020 we have selected Kapur J et al., Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus,

For December 2019, we have selected: Cree et al., Inebilizumab for the treatment of neuromyelitis optica (N-MOmentum): a double-blind, randomised placebo-controlled  phase 2/3 trial Lancet 2019 Epub ahead of print Sept 5.

This month’s selected paper addresses the risk of neurological deficits in people with cavernomas treated with antithrombotic medication. Perhaps counter-intuitively, the authors report a lower risk of intracerebral haemorrhage in patients taking antithrombotic medication (mostly antiplatelet therapy). The study therefore provides reassurance for clinicians managing patients with this relatively common, and often incidental, vascular finding that antithrombotic therapy does not appear harmful; conversely, there could be some benefit, but this requires further evaluation in a randomised controlled trial.

This month’s selected paper is a working group report that addresses a recently described disorder, limbic-predominant age-related TDP-43 encephalopathy (LATE), which is emerging as an important cause of cognitive impairment in the elderly. The group make recommendations for standardised neuropathological evaluation and identify research avenues to better understand this evolving new disease phenotype.

For September 2019, we have selected two scientific papers with a common theme: Goadsby et al., Trial of galcanezumab in prevention of episodic cluster headache NEJM 2019; 381: 132-41, and Lipton et al., Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine NEJM 2019; 381: 142-9.

For August 2019, we have selected Wilson, Sample et al. Clinical metagenomic sequencing for diagnosis of meningitis and encephalitis. N Eng J Med 2019; 380:24;2327-2340